Clinical-stage AI company Insilico Medicine has nominated a novel small molecule inhibitor known as ISM9274 as a preclinical candidate for cancer treatment. The company used its PandaOmics AI platform to analyze genomic data from more than 90 tumor types and identified CDK12 as a promising target for multiple cancers including triple-negative breast cancer, lung cancer,…
Insilico Medicine AI yields kidney fibrosis drug candidate
Insilico Medicine (Hong Kong) has announced that its AI-enabled drug discovery platform has yielded a preclinical candidate for kidney fibrosis. The company says the preclinical candidate has optimal pharmacological and pharmacokinetic profiles. In addition, it has successfully tested the candidate in both in vitro and in vivo preclinical studies. Insilico Medicine aims to advance the candidate…